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Description
Oxytocin is a peptide hormone best known for its 
roles in childbirth and breastfeeding. It is released in 
large amounts from the body’s pituitary gland during 
labor, causing contractions of the uterus to facilitate 
birth. It also stimulates contractions during the third 
stage of labor—separation of the placenta from the 
uterine wall and compression of maternal blood 
vessels after delivery of the placenta.1 When uterine 
contractions are not strong enough to compress blood 
vessels, postpartum hemorrhage (PPH) can threaten a 
woman’s life. In this situation, a woman will be given 
a uterotonic medicine, such as oxytocin, to stimulate 
contractions and stop the bleeding.
Obstetric hemorrhage is estimated to cause 25 percent 
of all maternal deaths and is the leading direct cause 
of maternal mortality worldwide.2 In Africa and 
Asia, nearly a third of pregnancy-related deaths are 
associated with PPH.1 The World Health Organization 
(WHO) and other international bodies recommend 
that all women giving birth should be offered 
uterotonics during the third stage of labor for the 
prevention of PPH.*  
According to the WHO, oxytocin is the preferred drug 
for prevention and initial treatment of PPH because it 
is effective in two to three minutes after injection, can 
be used in all women, and is more stable in storage 
than other uterotonics.3,4 WHO, with the Partnership 
for Maternal, Newborn, and Child Health, lists 
oxytocin as a first-line drug for induction of labor and 
the prevention and management of PPH.5 The United 
Nations Population Fund (UNFPA) and its partners 
have identified oxytocin as one of four priority 
medicines that can save mothers’ lives during difficult 
pregnancies and childbirth.6 
The standard dose of oxytocin for preventing 
PPH is 10 international units (IU) administered 
intramuscularly or intravenously (IV) within a few 
minutes after birth. If a woman is experiencing 
heavy bleeding after delivery, the WHO recommends 
intravenous oxytocin (10-IU initial dose) up to 40 IU.  
Oxytocin can be administered as an IV infusion of 20 
IU in 1 liter of IV fluid at 60 drops per minute, and 
continued at 20 IU in 1 liter of IV fluid at 40 drops  
per minute until hemorrhage stops.7 Oxytocin is  
most commonly available in either 5- or 10-IU  
glass ampoules. 
In 2012, the United Nations Commission on Life-
Saving Commodities for Women and Children 
endorsed oxytocin as one of its 13 Life-Saving 
Commodities, catalyzing inter-organizational efforts 
to overcome several commodity-specific barriers 
currently inhibiting women in the developing world 
from benefiting from the drug. 
Efficacy 
WHO has determined that, as a package, 
active management of the third stage of labor 
(administration of a uterotonic soon after birth of 
the baby, delayed cord clamping, and delivery of 
the placenta by controlled cord traction and uterine 
massage) can reduce PPH by as much as 60 percent.8 
WHO also reviewed the available evidence for using 
oxytocics for treatment of PPH, and while both 
oxytocin and ergometrine were similarly effective, 
ergometrine is associated with more adverse effects, 
especially vomiting and high blood pressure.8 
Current program/sector use 
Oxytocin is used worldwide for several indications.  
As noted above, it is the WHO preferred uterotonic 
for prevention and treatment of PPH and it is also 
used to induce and augment labor. In some  
developed countries, it is used to initiate or increase 
breast-milk production. 
In developing countries, oxytocin is commonly 
used in clinical environments where a skilled birth 
attendant and refrigeration are available. However, 
use of oxytocin for the indications noted previously 
is not universal and other drugs are also being used 
for induction and augmentation of labor, and for 
prevention or treatment of PPH.9 This is for a variety 
of reasons, including changes in recommendations 
over time, differences in country-level protocols and 
* In settings where oxytocin is unavailable, the use of other injectable uterotonics, such as ergometrine, or oral misoprostol (600 μg) is recommended.  
   Please see the Caucus product brief on misoprostol for more information.
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guidelines, and differences in the availability, cost, and 
storage requirements for the various drugs. 
Oxytocin in the Uniject™* injection system (oxytocin 
in Uniject), a prefilled, single-dose injection system, 
has been used successfully by skilled providers in 
health facilities. Research on the use of oxytocin in 
Uniject for the prevention of PPH during home and 
community-level deliveries has been conducted in 
Ghana, India, Mali, Senegal, and Vietnam.10-14
Work is underway to increase access to oxytocin 
by making it more heat stable and easier to use, 
particularly for developing-country settings with 
limited access to skilled birth attendants and 
refrigeration. A number of organizations are 
investigating potential improvements to the heat 
stability of oxytocin, including a consortium made 
up of the WHO, the International Confederation of 
Midwives, and pharmaceutical companies, among 
others.15 Some of these organizations are also seeking 
to make oxytocin easier to deliver through non-
parenteral routes, such as dry powder inhalation. 
Manufacturer/supplier 
Oxytocin is a generic drug no longer subject to patent 
protection and is widely produced and distributed 
around the world. Two oxytocin brand names are 
broadly recognized: Syntocinon,© which is marketed 
by Novartis, and Pitocin©, which is marketed by 
Pfizer in some countries and other producers in other 
countries. There are multiple generic manufacturers 
of oxytocin in almost all countries that have an active 
sterile injectables pharmaceutical manufacturing 
sector, including Argentina, Bangladesh, China, India, 
Indonesia, and Pakistan. One manufacturer, Instituto 
Biologio Argentino (BIOL) in Argentina, has the 
capacity to manufacture oxytocin in Uniject. 
As noted above, oxytocin, whether packaged in 
ampoules or a prefilled injection device such as 
Uniject™, is a heat-sensitive product. Depending 
upon the manufacturer and regulatory agency 
specification, oxytocin products should be stored at 
either controlled room temperature (25°C or less) or 
refrigerated storage (2°–8°C) in order to ensure quality 
and comply with the labeled storage conditions.  
There is widespread inconsistency in the labeled 
storage conditions for oxytocin from various 
manufacturers, which can lead to confusion about 
proper storage practices. 
Registration status 
Oxytocin is often registered for multiple obstetric 
indications, including prevention and treatment 
of PPH, as well as induction of labor. Due to the 
large number of manufacturers producing oxytocin 
globally, a complete listing of all manufacturers and 
their corresponding country registrations is beyond 
the scope of this brief; however, almost all countries 
have one or more registered oxytocin product. 
Oxytocin in Uniject is currently registered for 
commercial sale in Argentina, Bolivia, Ecuador, 
Guatemala, Honduras, Nicaragua, Paraguay, and 
Uruguay by BIOL. Modest commercial sales of the 
product are underway in Argentina. 
Public-sector price agreements 
According to the International Drug Price Indicator 
Guide for prices in 2011, the median cost to procurers 
of oxytocin (both nonprofits such as UNFPA and for-
profit organizations that sell to charitable groups) was 
US$0.15 per 10-IU ampoule.16 The median cost for 
governments purchasing from agencies such as these 
is US$0.22, but the cost can be as low as US$0.04. 
There are no known global public-sector price 
agreements for oxytocin. Governments can purchase 
oxytocin products that are registered in their country 
and can negotiate the price with the distributor that 
holds the market approval. 
Oxytocin is one of the reproductive health commodities 
covered under the WHO prequalification system. 
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For more information on the Caucus on New and Underused RH Technologies, please visit our web page at  
http://www.rhsupplies.org/working-groups/caucus-on-newunderused-rh-technologies.html.
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